SUBSEQUENT EVENTS |
9 Months Ended |
---|---|
Sep. 30, 2023 | |
SUBSEQUENT EVENTS | |
SUBSEQUENT EVENTS | NOTE 18 – SUBSEQUENT EVENTS
On October 9, 2023 the Company entered into a purchase agreement to acquire an artificial intelligence platform, which aims in drug repositioning and repurposing. The purchase price for the acquisition amounted to €300,000 ($318,540) (the “Cash Consideration”) payable in fifteen equal monthly installments and 280,000 shares of authorized and issued restricted common stock of the Company for the amount of $700,000 at an issuance price of $2.50 per share (the “Stock Consideration”). |